MT2004-30: Tomotherapy for Solid Tumors

Inclusion Criteria: * Diagnosis Patients must have had histologic verification of malignancy at original diagnosis. Diseases included are: * Ewing's Family Tumors (ES/PNET/DSRCT): metastatic at the time of diagnosis and/or relapsed after therapy * Renal tumors: relapsed (all histology-Wilm's tumor) or at diagnosis (clear cell sarcoma and Rhabdoid tumor), * Hepatoblastoma: metastatic at the time of diagnosis and/or relapsed after therapy * Rhabdomyosarcoma: metastatic at the time of diagnosis and/or relapsed after therapy * Soft tissue sarcomas: chemotherapy responsive metastatic disease or chemotherapy responsive relapsed disease * Primary Malignant Brain Neoplasms at diagnosis and/or relapse * Retinoblastoma: disseminated at diagnosis and/or relapsed * Other High Risk Metastatic or Relapsed Solid Tumors: To be approved by two or more physicians on the study committee * Disease Status: Patients must have either: 1) no evidence of disease or 2) stable, non-progressive disease (defined as non-progressive abnormalities on physical exam or computated tomography (CT) and/or magnetic resonance imaging \[MRI\]) within 4 weeks of study entry. * Age: Patients must be 0-70 years of age at the time of study entry. * Performance Level: Karnofsky \> or = 50% for patients \> 10 years of age and Lansky \> or = 50% for patients \< or = 10 years of age. Note: Neurologic deficits in patients with central nervous system (CNS) tumors must be stable for a minimum of 1 week prior…